 |
Article dans une revue
Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola
Abstract : Human African Trypanosomiasis may become manageable in the next decade with fexinidazole. However, currently stage
diagnosis remains difficult to implement in the field and requires a lumbar puncture. Our study of an Angolan cohort of T. b.
gambiense-infected patients used other staging criteria than those recommended by the WHO. We compared WHO criteria (cell
count and parasite identification in the CSF) with two biomarkers (neopterin and CXCL-13) which have proven potential to
diagnose disease stage or relapse. Biological, clinical, and neurological data were analysed from a cohort of 83 patients. A neopterin
concentration below 15.5 nmol/L in the CSF denoted patients with stage 1 disease, and a concentration above 60.31 nmol/L
characterized patients with advanced stage 2 (trypanosomes in CSF and/or cytorachia higher than 20 cells) disease. CXCL-13
levels below 91.208 pg/mL denoted patients with stage 1 disease, and levels of CXCL-13 above 395.45 pg/mL denoted patients with
advanced stage 2 disease. Values between these cut-offs may represent patients with intermediate stage disease. Our work supports
the existence of an intermediate stage in HAT, and CXCL-13 and neopterin levels may help to characterize it.
https://hal-unilim.archives-ouvertes.fr/hal-02378676
Contributeur : Elisabeth Grelier Connectez-vous pour contacter le contributeur
Soumis le : lundi 25 novembre 2019 - 12:24:11
Dernière modification le : samedi 26 mars 2022 - 04:24:08
Contributeur : Elisabeth Grelier Connectez-vous pour contacter le contributeur
Soumis le : lundi 25 novembre 2019 - 12:24:11
Dernière modification le : samedi 26 mars 2022 - 04:24:08
Lien texte intégral
